Sherwin Sattarzadeh

Sherwin Sattarzadeh leads operations at Damora Therapeutics, which is developing mutant-calreticulin-targeted therapies for essential thrombocythemia and myelofibrosis. Previously, he spent 10 years at Blueprint Medicines in roles including Chief Business Officer and Head of Regulatory Affairs, and contributed to the global approvals of AYVAKIT, GAVRETO, CERDELGA, and MOZOBIL.

Career

Cosigned byLoading...

CosignedSign in to view

Based in: Winchester

Damora Therapeutics

Until Present

COO

Profile name

Company name

Company name

Profile name

Company name

Company name

Profile name

Company name

Company name

Profile name

Company name

Company name

Profile name

Company name

Company name

Sherwin Sattarzadeh

Damora Therapeutics

Curated Lists

List Inclusions